Immune status evaluation of patients with chronic heart failure

Cytokine

Volumn 37, Issue 2, 2007, Pages 150-154

  Myrianthefs, Pavlos M ^a   Lazaris, Nikolaos ^a   Venetsanou, Kyriaki ^a   Smigadis, Nikolaos ^b   Karabatsos, Elias ^a   Anastasiou Nana, Maria I ^a   Baltopoulos, George J ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b 1st IKA Hospital   (Greece)

Author keywords

Chronic heart failure; Cytokines; Immune system; Lipopolysaccharide; Tolerance

Indexed keywords

CYTOKINE; ENDOTOXIN; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; BLOOD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; HEART FAILURE; HEART FUNCTION; HUMAN; IMMUNE SYSTEM; INCUBATION TIME; INFECTION; INFLAMMATION; MALE; PRIORITY JOURNAL;

CARDIAC OUTPUT, LOW; CHRONIC DISEASE; CYTOKINES; HUMANS; IMMUNE SYSTEM; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED;

EID: 34247869004     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2007.03.007     Document Type: Article

References (41)

1. Anker S.D., and von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 90 (2004) 464-470
2. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol 95 (2005) 3C-8C
3. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91 (2002) 988-998
4. Aukrust P., Gullestad L., Ueland T., Dama J.K., and Yndestad A. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med 37 (2005) 74-85
5. Levine B., Kalman J., Mayer L., Fillit H.M., and Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990) 236-241
6. Aukrust P., Ueland T., Lien E., et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 83 (1999) 376-382
7. Torre-Amione G., Kapadia S., Benedict C.R., Oral H., Young J.B., and Mann D.L. Pro-inflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27 (1996) 1201-1206
8. Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., and Mann D.L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation 103 (2001) 2055-2059
9. Ferrari R., Bachetti T., Confortini R., et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 92 (1995) 1479-1486
10. Testa M., Yeh M., Lee P., et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 28 (1996) 964-971
11. Rauchhaus M., Doehner W., Francis D.P., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102 (2000) 3060-3067
12. Bone R.C., Balk R.A., Cerra F.B., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: ACCP/SCCM consensus conference. Chest 101 (1992) 1644-1655
13. Marshall J.C., Vincent J.L., Fink M.P., et al. Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the fifth Toronto sepsis roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med 31 (2003) 1560-1567
14. Vincent J.L., and Abraham E. The last 100 years of sepsis. Am J Respir Crit Care Med 173 (2006) 256-263
15. Waage A., Halstensen A., and Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1 8529 (1987) 355-357
16. Martin C., Boisson C., Haccoun M., Thomachot L., and Mege J.L. Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med 25 (1997) 1771-1773
17. Docke W.-D., Randwo F., Syrbe U., et al. Monocyte deactivation in septic patients: restoration by INF-γ treatment. Nat Med 3 (1997) 678-681
18. Shimokawa H., Kuroiwa-Matsumoto M., and Takeshita A. Cytokine generation capacities of monocytes are reduced in patients with severe heart failure. Am Heart J 136 (1998) 991-1002
19. Larrick J.W., Hirata M., Zheng H., et al. Novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity. J Immunol 152 1 (1994) 231-240
20. Myrianthefs P., Karatzas S., Venetsanou K., et al. Seasonal variation in whole blood cytokine production after LPS stimulation in normal individuals. Cytokine 24 (2003) 286-292
21. Myrianthefs P., Karatzas S., Venetsanou K., and Baltopoulos G. LPS tolerance in septic ICU patients: laboratory and technical considerations. Surg Infect 5 1 (2004) 63-64
22. Munoz C., Carlet J., Fitting C., Misset B., Bleriot J.P., and Cavailoon J.M. Dysregulation of in vitro production by monocytes during sepsis. J Clin Invest 88 (1991) 1747-1754
23. Ertel W., Kremer J.P., Kenney J., et al. Down regulation of pro-inflammatory cytokine release in whole blood from septic patients. Blood 85 (1995) 1341-1347
24. West M.A., and Heagy W. Endotoxin tolerance: a review. Crit Care Med 30 (2002) S64-S73
25. Zhang M., and Tracey K.J. Tumor necrosis factor. In: Thomson A. (Ed). The cytokine handbook. 3rd ed. (1998), Academic Press, Great Britain 517-548
26. Panacek E.A., and Kaul M. IL-6 as a marker of excessive TNF-α activity in sepsis. Sepsis 3 (1999) 65-73
27. Mira J.P., Cariou A., Grall F., et al. Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality. JAMA 282 (1999) 561-568
28. Appoloni O., Dupont E., Vandercruys M., et al. Association of tumor necrosis factor-2 allele with plasma tumor necrosis factor-α levels and mortality from septic shock. Am J Med 110 (2001) 486-488
29. Gogos A.C., Drosou E., Bassaris H.P., and Skoutelia A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. JID 181 (2000) 176-180
30. Bolger A.P., and Anker S.D. Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications. Drugs 60 (2000) 1245-1257
31. Mann D.L. Targeted anticytokine therapy and the tailing heart. Am J Cardiol 95 (2005) 9C-16C
32. von Haehling S., Jankowska E.A., and Anker S.D. Tumour necrosis factor-alpha and the failing heart: pathophysiology and therapeutic implications. Basic Res Cardiol 99 (2004) 18-28
33. Bolger A.P., Sharma R., von Haehling S., et al. Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure. Am J Cardiol 90 (2002) 384-389
34. von Haehling S., Genth-Zotz S., Sharma R., Bolger A., Doehner W., Barnes P., et al. The relationship between age and production of tumour necrosis factor-α in healthy volunteers and patients with chronic heart failure. Int J Cardiol 90 2-3 (2003) 197-204
35. Matsumori A., Shioi T., Yamada T., Matsui S., and Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 89 3 (1994) 955-958
36. Vonhof S., Brost B., Stille-Siegener M., Grumbach I.M., Kreuzer H., and Figulla H.R. Monocyte activation in congestive heart failure due to coronary artery disease and idiopathic dilated cardiomyopathy. Int J Cardiol 63 (1998) 237-244
37. Genth-Zotz S., von Haehling S., Bolger A.P., et al. Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. Am J Cardiol 90 (2002) 1226-1230
38. Kruger S., Kunz D., Graf J., et al. Endotoxin sensitivity and immune competence in chronic heart failure. Clin Chim Acta 343 (2004) 135-139
39. Conraads V.M., Bosmans J.M., Schuerwegh A.J., et al. Intracellular monocyte cytokine production and CD14 expression are up-regulated in severe vs. mild chronic heart failure. J Heart Lung Transpl 24 (2005) 854-859
40. Sharma R., von Haehling S., Rauchhaus M., et al. Whole blood endotoxin responsiveness in patients with chronic heart failure: the importance of serum lipoproteins. Eur J Heart Fail 7 (2005) 479-484
41. Sharma R., Bolger R., Rauchhaus M., et al. Cellular endotoxin desensitization in patients with severe chronic heart failure. Eur J Heart Fail 7 (2005) 865-868